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Introduction
There is a consensus regarding the need to move beyond
antibiotic therapy if we want to improve outcomes of
hospitalized patients with community-acquired pneumonia
(CAP). However, there is a lack of consensus regarding the use
of steroids as adjunctive therapy in patients with CAP.
Eleven meta-analyses have been already published in the
field of steroids and CAP [1-11]. A primary problem with
several of these meta-analyses is the inclusion of studies
with important methodological weaknesses. In addition, in
a recent meta-analysis which was published in the American
Journal of Emergency Medicine [10], the authors incorporated
3 manuscripts which were written in Chinese, making it
impossible for us to evaluate the quality of those research
studies. At present, we have more meta-analyses published
on the topic of steroids and CAP than original randomized
clinical trials (RCTs), with some of them arriving to different
conclusions. Meta-analyses are considered the highest level of
evidence when they are based on high-quality RCTs, but this
is not the case in the field of steroids and CAP. Because of the
above, the controversy regarding the use of steroids in patients
with CAP will continue until further high quality research is
published.
With all these caveats in mind, after reviewing recent randomized
clinical trials [12-19] we consider that there is enough evidence
to recommend the use of steroids only in a well selected group
of hospitalized patients with CAP. We also consider that the
current level of evidence in favor of steroid is weak, and that
there is a significant possibility that future studies may alter our
current recommendations. In this editorial, we summarize our
approach to the use of steroids in hospitalized patients with CAP
at the University of Louisville Hospital.

Who are the candidates for steroid
therapy?
Different studies have used different inclusion criteria to
define a patient as a candidate for steroid therapy. Steroids are
supposed to improve outcomes by controlling an exaggerated or
dysregulated host inflammatory response. Hospitalized patients
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with CAP with exaggerated or dysregulated inflammation are
likely to present with severe CAP with clinical and laboratory
evidence of sepsis. Translating these concepts into clinical
practice, we consider patients as candidates for steroid therapy if
they have clinical or laboratory manifestations compatible with
early sepsis. Clinically, the patient may have respiratory failure
requiring ventilator support or the need for high FIO2 (>50%),
hypotension unresponsive to fluid resuscitation, or evidence of
newly developed organ dysfunction. Elevated levels of C-reactive
protein (CRP) have been associated with high cytokine levels
in patients with CAP [20]. Elevated levels of lactic acid and or
the presence of metabolic acidosis are associated with sepsis
and poor outcomes in patients with CAP [21,22]. Based on the
above, from a laboratory perspective, we consider patients as
candidates for steroid therapy if they have CRP greater than
150 mg/L, lactic acid greater than 4 mmol/L, or arterial pH
is lower than 7.30. There are no clinical or laboratory criteria
that are diagnostic of sepsis, then the presence of any criteria to
support diagnosis of sepsis should not be clearly explained by an
alternative clinical diagnosis.
In an attempt to limit steroid adverse events, most clinical
studies excluded patients who are at risk for adverse events. After
reviewing exclusion criteria from all studies, we recommend
that patients will not be candidates for steroid therapy if they
have a recent history of gastrointestinal bleeding, uncontrolled
diabetes, or if they are severely immunocompromised.
Retrospective studies reported that the use of steroids in
patients with influenza pneumonia is associated to worse clinical
outcomes [23,24]. The presence of influenza as etiology of CAP
was used as an exclusion criterion in some of the clinical trials
of steroid use in hospitalized patients with CAP. Production
of Interferon-gamma (IFN-γ) interferes with replication of
influenza and other virusues [25]. It can be speculated that
steroids, by inhibiting IFN-γ, may facilate viral replication in
patients with influenza CAP or in any other form of viral CAP.
Until further studies define the role of steroids in patients with
CAP of viral etiology, we recommend that these patients should
not be considered candidates for steroid use. If a patient is seen
in the emergency room with a clinical and laboratory picture
compatible with CAP and exaggerated inflammatory response,
we recommend not to wait for microbiological tests to define
if viral CAP is present. If after initiation of steroid therapy, the
microbiological workup indicates viral CAP, steroids can be
discontinued at that point.
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Hospitalized Patient with CAP: Candidate for Steroid Therapy
A. At least one of the following:
1. Respiratory failure with >50% FIO2
2. Hypotension unresponsive to fluids
3. Evidence of new organ dysfunction

Start methylprednisolone 0.5 mg/kg IV q 12
hours with first dose given as soon as possible,
for a total of 5 days.

Plus

B. At least one of the following:
1. CRP greater than 15 mg/dl
2. Lactic acid greater than 4 nmol/L
3. Metabolic acidosis with pH < 7.30

Candidate for
steroid therapy:
Patient meeting
criteria A, plus B,
plus C

If the patient reaches clinical stability and will
be switched from IV to oral antibiotics, IV
steroids can be switched to oral prednisone
50mg per day to complete the 5 days of high
dose steroid therapy.

Plus

C. No evidence of any of the following:
Recent history of gastrointestinal bleeding
Uncontrolled diabetes
Severe immunocompromised host
Influenza or other viral etiology of CAP

After 5 days of high dose steroids, followed with
5 days prednisone tapering dose with 40mg,
30mg, 20mg, 10mg, and 5mg, per day.

Figure 1 Criteria to define a patient as a candidate for steroid use and suggested course of therapy.

What steroids should be used, and for
how long?
Investigators have used different types of steroids, different
doses and different duration of therapy. In an attempt to
obtain early maximal effect, we consider initially the use of the
intravenous route, even in patients who are able to take oral
medications. Our recommendation is to use methylprednisolone
0.5 mg/kg IV every 12 hours for 5 days. If a patient has a rapid
improvement, reaches clinical stability, and antibiotic therapy
is switched from intravenous to oral, we recommended at that
point to switch from intravenous methylprednisolone to oral
prednisone 50mg daily to complete the 5 days of therapy.
A rapid discontinuation of steroid therapy in patients with severe
CAP may produce a rebound of the inflammatory response. We
are participating in the current US Department of Veterans
Affairs trial of steroids in patients with CAP admitted to the ICU,
the Extended Steroid in CAP (ESCAPe) study (NCT01283009).
In this study, after initial high dose, steroid dose is tapered in
an attempt to prevent rebound inflammation. Considering the
above, we recommend a total of 10 days of steroids. Initial five
days of high dose steroids with a tapering dose of prednisone for
the following 5 days with doses of 40mg, 30mg, 20mg, 10mg,
and 5mg per day.

same phenomenon described in Streptococcus pneumoniae
meningitis and PCP may be occurring in patients with CAP [28].
Our recommendation is to administering steroids concurrently
with antibiotics or as soon as possible once a patient has
been identified as a candidate for steroid therapy. The initial
treatment for severe CAP is commonly implemmented by
emergency medicine physicians or hospitalists even if patients
are subsequently admitted to the ICU. It is thus important for
these clinicians to be updated with the current literature on
steroids and CAP.

Conclusion
Steroids may improve clinical outcomes in hospitalized patients
with CAP who have an exaggerated inflammatory response.
Based on our analysis of the current evidence, the flowchart
presented in Figure 1 was developed as a guideline for the
identification of patients who may benefit from steroid use.
Until further RCTs are published, practitioners should continue
to use clinical judgment, weight potential benefit and risk, and
define if the individual patient is a candidate for steroid use.
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